Cosmos Health participated in World Health Expo Dubai, showcasing its nutraceutical brands and expanding global partnerships.
Quiver AI Summary
Cosmos Health Inc. announced its participation in the World Health Expo Dubai 2026, one of the largest global healthcare exhibitions, where it showcased its portfolio of nutraceutical and wellness brands, particularly the Sky Premium Life line. The event attracted over 235,000 visitors and featured 4,300 exhibitors from more than 180 countries, offering a platform for networking and exploring healthcare trends. Cosmos Health emphasized its proprietary products and vertical manufacturing capabilities, aiming to expand its international presence and secure new distribution agreements, particularly in North America and other regions. CEO Greg Siokas noted the potential for growth through strategic partnerships and highlighted the company's ongoing commitment to brand development and value creation.
Potential Positives
- Participation in the World Health Expo Dubai 2026 positions Cosmos Health to enhance its global visibility and network within the healthcare sector.
- The company showcased its growing portfolio of proprietary nutraceutical and wellness brands, indicating strong market demand and expanding distribution opportunities.
- Strategic meetings during the Expo with potential partners from various countries could lead to significant new agreements, furthering the company's expansion efforts.
- Cosmos Health's focus on R&D partnerships and the integration of advanced technologies positions it for long-term innovation and growth in addressing major health disorders.
Potential Negatives
- Participation in a major international expo highlights the company's reliance on external partnerships and global markets for growth, indicating potential vulnerabilities in its current business model.
- The mention of ongoing negotiations and potential agreements suggests that the company's expansion plans are still at a formative stage and not yet finalized, implying uncertainty about future revenues.
- References to risks, such as financing challenges and the impact of geopolitical events like the war in Ukraine, could raise concerns among investors regarding the company's stability and resilience in a volatile market.
FAQ
What is the World Health Expo Dubai 2026?
The World Health Expo Dubai 2026, formerly Arab Health, is a major healthcare exhibition featuring over 4,300 exhibitors and 235,000 visitors.
Where was Cosmos Health’s booth located at the Expo?
Cosmos Health exhibited at Booth SA.A79 at the Dubai Exhibition Centre during the World Health Expo Dubai 2026.
What brands did Cosmos Health showcase at the event?
Cosmos Health showcased its Sky Premium Life®, C-Scrub®, and Mediterranation® brands, among others during the exhibition.
What was the significance of Cosmos Health's participation?
Participating allowed Cosmos Health to expand its global footprint, engage potential partners, and strengthen strategic relationships in healthcare.
How is Cosmos Health expanding its market presence?
Cosmos Health is expanding through distribution agreements, product introductions, and entering new markets like North America with NOOR line.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COSM Insider Trading Activity
$COSM insiders have traded $COSM stock on the open market 16 times in the past 6 months. Of those trades, 16 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COSM stock by insiders over the last 6 months:
- GRIGORIOS SIOKAS (Chief Executive Officer) has made 16 purchases buying 2,703,030 shares for an estimated $1,286,999 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$COSM Revenue
$COSM had revenues of $17.1M in Q3 2025. This is an increase of 37.86% from the same period in the prior year.
You can track COSM financials on Quiver Quantitative's COSM stock page.
$COSM Hedge Fund Activity
We have seen 11 institutional investors add shares of $COSM stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC added 241,775 shares (+260.5%) to their portfolio in Q4 2025, for an estimated $120,403
- CITADEL ADVISORS LLC added 128,776 shares (+133.1%) to their portfolio in Q3 2025, for an estimated $142,941
- VIRTU FINANCIAL LLC removed 87,515 shares (-83.8%) from their portfolio in Q3 2025, for an estimated $97,141
- JANE STREET GROUP, LLC removed 29,218 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $32,431
- XTX TOPCO LTD added 28,791 shares (+78.4%) to their portfolio in Q3 2025, for an estimated $31,958
- STATE STREET CORP added 20,500 shares (+82.9%) to their portfolio in Q4 2025, for an estimated $10,209
- STONEX GROUP INC. removed 19,300 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,611
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its participation in World Health Expo Dubai 2026 (formerly Arab Health), one of the world’s largest and most influential healthcare exhibitions and conferences.
The Expo was held February 9–12, 2026, at the Dubai Exhibition Centre in Expo City Dubai, United Arab Emirates, where Cosmos Health exhibited at Booth SA.A79.
The event, which accommodates more than 235,000 visitors and over 4,300 exhibitors from more than 180 countries, brings together healthcare leaders, distributors, manufacturers, and innovators to explore emerging trends, foster strategic partnerships, and advance international collaboration within the healthcare sector.
At the exhibition, Cosmos Health showcased its growing portfolio of proprietary nutraceutical and wellness brands, led by its flagship Sky Premium Life® line of nutraceuticals, which continues to gain global traction through expanded distribution agreements, new product introductions, and increasing international demand. The brand’s premium formulations have strengthened its presence across the key markets in Europe and the Middle East, while its recent expansion into the North American market through the NOOR line is supported by Cosmos Health’s U.S.-based manufacturing capabilities.
The Company also highlighted several of its other healthcare and consumer brands, including C-Scrub® , its antiseptic wash formulated to deliver reliable antimicrobial properties and support effective hand and skin hygiene, as well as Mediterranation® , its proprietary luxury nutritional supplement line featuring formulations that incorporate organic herbs and plant extracts traditionally sourced from Greece and the broader Mediterranean region, including crataegus, hibiscus, dittany of Crete, oregano, mastic, and kritamos.
The Company’s presence at the Expo provided an opportunity to raise awareness of its vertically integrated manufacturing capabilities and to engage with potential commercial partners, distributors, and industry stakeholders.
Greg Siokas, CEO of Cosmos Health, stated: “Participating in World Health Expo Dubai underscores our commitment to expanding the global footprint of our proprietary brands. Sky Premium Life continues to gain international momentum, and this platform enables us to strengthen strategic relationships, expand distribution opportunities, and showcase the depth and quality of our portfolio. During the exhibition, we held highly productive meetings with participating parties from new regions and territories, ranging from Japan and China to several Latin American countries, and we are currently in the process of advancing several potential agreements. We remain focused on disciplined growth, brand development, and long-term value creation.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (
www.sec.gov
). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
[email protected]
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/94a84d85-d3b0-4fc8-90ce-e6d6e573c9f1